TICKERNERD
Menu
VOGXHealthcare · Biotechnology

VOGX Stock Forecast: Vogenx, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$33
+9.54% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap
$485.9M
Ticker Nerd rank
1 / 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
+1.7%
From high
−3.8%
From low
+151.6%
$13
$34
Range since 12 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

VOGX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vogenx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
54
Revisions
37
Value
15
Growth
8
Accruals
8
Momentum
8
Quality
4
Volatility
3
Issuance
1

Size (54): Smaller than most of the companies we track.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VOGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VOGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 12 Aug 2026Adjusted close, US dollars
$10$15$20$25$30$35Aug 26Aug 26Aug 26Sep 26VOGX

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Sept 2026WBB SecuritiesInitiatesSpeculative Buy$42
1 Sept 2026Jones TradingInitiatesBuy$55

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VOGX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VOGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

VOGX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Aug 26Aug 26Aug 26Sep 26VOGXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VOGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Vogenx, Inc. (VOGX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
−179.2×

Cheaper than 99% of US stocks

EV / EBITDA
−115.7×

Cheaper than 97% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
157.3%

Higher than 98% of US stocks

Return on assets
−212.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vogenx, Inc. (VOGX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vogenx, Inc. has a market value of $485.9M and an enterprise value of $172.7M.

  • Shares outstanding: 13.9M.

  • Vogenx, Inc. employs 4 people.

market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

VOGX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VOGXVogenx, Inc.$485.9M
1
EIKNEikon Therapeutics, Inc.$483.7M
1
CAPRCapricor Therapeutics, Inc.$481.4M
9
PRTAProthena Corp. Plc$480.7M
98
IRDOpus Genetics, Inc.$491.6M
58
ENTXEntera Bio Ltd.$491.7M
49
ZURAZura Bio Ltd.$494.3M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vogenx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VOGX news & analysis

Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering

PRNewsWire · 17 Aug 2026positive

JonesTrading Institutional Services announced it served as sole book-running manager for Vogenx, Inc.'s $81.3 million initial public offering on NASDAQ. The offering comprised 6,250,000 shares of Vogenx common stock at $13.00 per share, priced at the high end of the proposed range.

Why it matters — The IPO's completion and pricing at the high end of the proposed range is notable for Vogenx watchers as it marks the company's public market debut and reflects demand for its shares.

FAQ

Frequently asked questions about VOGX stock

How does Ticker Nerd's model rank VOGX?

As at 12 Sept 2026, Vogenx, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (54 of 100).

What is the VOGX stock forecast for 2030?

No analyst covering Vogenx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VOGX are extrapolating price history, which says nothing about the business.

What does Vogenx, Inc. do?

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders.

What is the latest news on VOGX?

The most recent item we track (PRNewsWire, 17 Aug 2026): "Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering". JonesTrading Institutional Services announced it served as sole book-running manager for Vogenx, Inc.'s $81.3 million initial public offering on NASDAQ. The offering comprised 6,250,000 shares of Vogenx common stock at $13.00 per share, priced at the high end of the proposed range.

Company

About Vogenx, Inc.

Vogenx Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious metabolic and gastrointestinal disorders. Its current work centers on treatments for post-bariatric hypoglycemia and gastroparesis, with additional research in related rare metabolic conditions. The company’s lead program is mizagliflozin, an oral small-molecule SGLT1 inhibitor designed to address abnormal glucose absorption and other metabolic pathways in the gut. Vogenx also maintains a broader pipeline that includes additional drug candidates under evaluation for metabolic disease indications. The company serves the life sciences and drug development market, where it advances investigational therapies aimed at conditions with limited treatment options. Vogenx Inc. is headquartered in Raleigh, North Carolina and operates as a focused developer of novel medicines for metabolic and gastrointestinal disease areas.

CEO Mr. James Green · 4 employees · United States · https://vogenx.com